@article {Lensen2020.04.08.20033373, author = {Sarah Lensen and Archie Macnair and Sharon B Love and Victoria Yorke-Edwards and Nurulamin M Noor and Meredith Martyn and Alexandra Blenkinsop and Carlos Diaz-Montana and Graham Powell and Elizabeth Williamson and James Carpenter and Matthew R Sydes}, title = {Access to routinely collected health data for clinical trials {\textendash} review of successful data requests to UK registries}, elocation-id = {2020.04.08.20033373}, year = {2020}, doi = {10.1101/2020.04.08.20033373}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Clinical trials generally each collect their own data despite routinely-collected health data (RCHD) increasing in quality and breadth. Our aim is to quantify UK-based randomised controlled trials (RCTs) accessing RCHD for participant data, characterise how these data are used and thereby recommend how more trials could use RCHD.Methods We conducted a systematic review of RCTs accessing RCHD from at least one registry in the UK between 2013-2018, for the purposes of informing or supplementing participant data. A list of all registries holding RCHD in the UK was compiled. In cases where registries published release registers, these were searched for RCTs accessing RCHD. Where no release register was available, registries were contacted to request a list of RCTs. For each identified RCT, information was collected from all publicly available sources (release registers, websites, protocol etc.). The search and data extraction was undertaken between Jan-2019 and May-2019.Results We identified 160 RCTs accessing RCHD between 2013 and 2018 from a total of 22 registries; this corresponds to only a very small proportion of all UK RCTs (approximately 3\%). RCTs accessing RCHD were generally large (median sample size 1590), commonly evaluating treatments for cancer or cardiovascular disease. Most of the included RCTs accessed RCHD from NHS Digital (68\%), and the most frequently accessed datasets were mortality (76\%) and hospital visits (55\%). RCHD was used to inform the primary trial (82\%) and long-term follow-up (57\%). There was substantial variation in how RCTs used RCHD to inform participant outcome measures. A limitation was the lack of information and transparency from registries and RCTs with respect to which datasets have been accessed and for what purposes.Conclusions In the last five years, only a small minority of UK-based RCTs have accessed RCHD to inform participant data. We ask for improved accessibility, confirmed data quality and joined up thinking between the registries and the regulatory authorities.Registration PROSPERO CRD42019123088Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: a grant from HDRUK to support this project. MS reports grants from Health Data Research UK, during the conduct of the study; personal fees from Lilly Oncology, personal fees from Janssen, grants and non-financial support from Astellas, grants and non-financial support from Clovis Oncology, grants and non-financial support from Janssen, grants and non-financial support from Novartis, grants and non-financial support from Pfizer, grants and non-financial support from Sanofi-Avents, outside the submitted work. SBL reports travel and subsistence from Federal Drugs Agency, outside the submitted work.Clinical Protocols https://www.crd.york.ac.uk/prospero/ Funding StatementThis work was supported by Health Data Research UK, an initiative funded by UK Research and Innovation, Department of Health and Social Care (England) and the devolved administrations, and leading medical research charities, Medical Research Council MC_UU_12023/24Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll of the information is publicly available. The dataset and technical appendices are available upon request as per the controlled access approach of the MRC CTU at UCL. Please contact the corresponding author for more informationHDR UKHealth Data Research UKNIHRNational Institute for Health ResearchRCTrandomised controlled trialRCHDroutinely-collected health dataUKCRCUK Clinical Research Collaboration}, URL = {https://www.medrxiv.org/content/early/2020/04/10/2020.04.08.20033373}, eprint = {https://www.medrxiv.org/content/early/2020/04/10/2020.04.08.20033373.full.pdf}, journal = {medRxiv} }